Literature DB >> 20380812

Photodynamic therapy targeting neuropilin-1: Interest of pseudopeptides with improved stability properties.

Noémie Thomas1, Marlène Pernot, Régis Vanderesse, Philippe Becuwe, Ezatul Kamarulzaman, David Da Silva, Aurélie François, Céline Frochot, François Guillemin, Muriel Barberi-Heyob.   

Abstract

The general strategy developed aims to favor the vascular effect of photodynamic therapy by targeting tumor vasculature. Since angiogenic endothelial cells represent an interesting target to potentiate this vascular effect, we previously described the conjugation of a photosensitizer to a peptide targeting neuropilins (NRPs) over-expressed specially in tumor angiogenic vessels and we recently characterized the mechanism of photosensitization-induced thrombogenic events. Nevertheless, in glioma-bearing nude mice, we demonstrated that the peptide moiety was degraded to various rates according to time after intravenous administration. In this study, new peptidases-resistant pseudopeptides were tested, demonstrating a molecular affinity for NRP-1 and NRP-2 recombinant chimeric proteins and devoid of affinity for VEGF receptor type 1 (Flt-1). To argue the involvement of NRP-1, MDA-MB-231 breast cancer cells were used, strongly over-expressing NRP-1 receptor. We evidenced a statistically significant decrease of the different peptides-conjugated photosensitizers uptake after RNA interference-mediated silencing of NRP-1. Peptides-conjugated photosensitizers allowed a selective accumulation into cells. In mice, no degradation was observed in plasma in vivo 4h after intravenous injection by MALDI-TOF mass spectrometry. This study draws attention to this potential problem with peptides, especially in the case of targeting strategies, and provides useful information for the future design of more stable molecules. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20380812     DOI: 10.1016/j.bcp.2010.03.036

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity.

Authors:  María Julia Lamberti; Natalia Belén Rumie Vittar; Viviana Alicia Rivarola
Journal:  World J Clin Oncol       Date:  2014-12-10

2.  Nanotechnology for photodynamic therapy: a perspective from the Laboratory of Dr. Michael R. Hamblin in the Wellman Center for Photomedicine at Massachusetts General Hospital and Harvard Medical School.

Authors:  Michael R Hamblin; Long Y Chiang; Shanmugamurthy Lakshmanan; Ying-Ying Huang; Maria Garcia-Diaz; Mahdi Karimi; Alessandra Nara de Souza Rastelli; Rakkiyappan Chandran
Journal:  Nanotechnol Rev       Date:  2015-08-07       Impact factor: 7.848

3.  Real-time monitoring of photocytotoxicity in nanoparticles-based photodynamic therapy: a model-based approach.

Authors:  Hamanou Benachour; Thierry Bastogne; Magali Toussaint; Yosra Chemli; Aymeric Sève; Céline Frochot; François Lux; Olivier Tillement; Régis Vanderesse; Muriel Barberi-Heyob
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

4.  New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy.

Authors:  Ezatul Ezleen Kamarulzaman; Amirah Mohd Gazzali; Samir Acherar; Céline Frochot; Muriel Barberi-Heyob; Cédric Boura; Patrick Chaimbault; Estelle Sibille; Habibah A Wahab; Régis Vanderesse
Journal:  Int J Mol Sci       Date:  2015-10-12       Impact factor: 5.923

5.  Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature.

Authors:  Vida Mashayekhi; Charlotte Op 't Hoog; Sabrina Oliveira
Journal:  J Porphyr Phthalocyanines       Date:  2019-12       Impact factor: 1.811

6.  New Targeted Gold Nanorods for the Treatment of Glioblastoma by Photodynamic Therapy.

Authors:  Zahraa Youssef; Nurlykyz Yesmurzayeva; Ludivine Larue; Valérie Jouan-Hureaux; Ludovic Colombeau; Philippe Arnoux; Samir Acherar; Régis Vanderesse; Céline Frochot
Journal:  J Clin Med       Date:  2019-12-13       Impact factor: 4.241

7.  PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer.

Authors:  Qiuxiao Shi; Ze Tao; Hao Yang; Qing Fan; Danfeng Wei; Lin Wan; Xiaofeng Lu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography.

Authors:  Albert Moussaron; Valérie Jouan-Hureaux; Charlotte Collet; Julien Pierson; Noémie Thomas; Laurence Choulier; Nicolas Veran; Matthieu Doyen; Philippe Arnoux; Fatiha Maskali; Dominique Dumas; Samir Acherar; Muriel Barberi-Heyob; Céline Frochot
Journal:  Molecules       Date:  2021-11-30       Impact factor: 4.411

9.  Multifunctional Peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI.

Authors:  Hamanou Benachour; Aymeric Sève; Thierry Bastogne; Céline Frochot; Régis Vanderesse; Jordane Jasniewski; Imen Miladi; Claire Billotey; Olivier Tillement; François Lux; Muriel Barberi-Heyob
Journal:  Theranostics       Date:  2012-09-29       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.